The emerging role of human esterases

Drug Metabolism and Pharmacokinetics

Volumn 27, Issue 5, 2012, Pages 466-477

  Fukami, Tatsuki ^a   Yokoi, Tsuyoshi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

Activation of prodrugs; Drug adverse reaction; Drug detoxification; Drug hydrolysis; Esterases

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ACYLAMINO ACID RELEASING ENZYME; ALBUMIN; ALDEHYDE DEHYDROGENASE; ALPHA BETA HYDROLASE DOMAIN CONTAINING 10; AMIDE; ARYLACETAMIDE DEACETYLASE; ARYLDIALKYLPHOSPHATASE; ARYLDIALKYLPHOSPHATASE 3; BAMBUTEROL; BIPHENYL HYDROLASE LIKE PROTEIN; CAPECITABINE; CARBOXYLESTERASE; CARBOXYMETHYLENEBUTENOLIDASE; CHOLINESTERASE; ESTER; ESTERASE; FLUTAMIDE; IRINOTECAN; MEVINOLIN; MYCOPHENOLIC ACID; OLMESARTAN; PHENACETIN; PILOCARPINE; RIFAMYCIN; SIMVASTATIN; SUXAMETHONIUM; THIOESTER; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID;

BLOOD TOXICITY; DETOXIFICATION; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME SPECIFICITY; HUMAN; LIVER TOXICITY; NEPHROTOXICITY; NONHUMAN; PROTEIN EXPRESSION; REVIEW; TISSUE DISTRIBUTION;

EID: 84866600954     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-12-RV-042     Document Type: Review

References (120)

1. Williams, J. A., Hyland, R., Jones, B. C., Smith, D. A., Hurst, S., Goosen, T. C., Peterkin, V., Koup, J. R. and Ball, S. E.: Drugdrug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab. Dispos., 32: 1201-1208 (2004).
2. Watanabe, A., Fukami, T., Nakajima, M., Takamiya, M., Aoki, Y. and Yokoi, T.: Human arylacetamide deacetylase is a principal enzyme in flutamide hydrolysis. Drug Metab. Dispos., 37: 1513-1520 (2009).
3. Watanabe, A., Fukami, T., Takahashi, S., Kobayashi, Y., Nakagawa, N., Nakajima, M. and Yokoi, T.: Arylacetamide deacetylase is a determinant enzyme for the difference in hydrolase activities of phenacetin and acetaminophen. Drug Metab. Dispos., 38: 1532-1537 (2010).
4. Nakajima, A., Fukami, T., Kobayashi, Y., Watanabe, A., Nakajima, M. and Yokoi, T.: Human arylacetamide deacetylase is responsible for deacetylation of rifamycins: rifampicin, rifabutin, and rifapentine. Biochem. Pharmacol., 82: 1747-1756 (2011).
5. Iwamura, A., Fukami, T., Higuchi, R., Nakajima, M. and Yokoi, T.: Human α/β hydrolase domain containing 10 (ABHD10) is a responsible enzyme for deglucuronidation of mycophenolic acid acyl-glucuronide in liver. J. Biol. Chem., 287: 9240-9249 (2012).
6. Holmes, R. S., Wright, M. W., Laulederkind, S. J., Cox, L. A., Hosokawa, M., Imai, T., Ishibashi, S., Lehner, R., Miyazaki, M., Perkins, E. J., Potter, P. M., Redinbo, M. R., Robert, J., Satoh, T., Yamashita, T., Yan, B., Yokoi, T., Zechner, R. and Maltais, L. J.: Recommended nomenclature for five mammalian carboxylesterase gene families: human, mouse, and rat genes and proteins. Mamm. Genome, 21: 427-441 (2010).
7. Fukami, T., Nakajima, M., Maruichi, T., Takahashi, S., Takamiya, M., Aoki, Y., McLeod, H. L. and Yokoi, T.: Structure and characterization of human carboxylesterase 1A1, 1A2, and 1A3 genes. Pharmacogenet. Genomics, 18: 911-920 (2008).
8. Imai, T.: Human carboxylesterase isozymes: catalytic properties and rational drug design. Drug Metab. Pharmacokinet., 21: 173-185 (2006).
9. Brzezinski, M. R., Abraham, T. L., Stone, C. L., Dean, R. A. and Bosron, W. F.: Purification and characterization of a human liver cocaine carboxylesterase that catalyzes the production of benzylecgonine and the formation of cocaethylene from alcohol and cocaine. Biochem. Pharmacol., 48: 1747-1755 (1994).
10. Xu, G., Zhang, W., Ma, M. K. and McLeod, H. L.: Human carboxylesterase 2 is commonly expressed in tumor tissues and is correlated with activation of irinotecan. Clin. Cancer Res., 8: 2605-2611 (2002).
11. Pindel, E. V., Kedishvili, N. Y., Abraham, T. L., Brzezinski, M. R., Zhang, J., Dean, R. A. and Bosron, W. F.: Purification and cloning of a broad substrate specificity human liver carboxylesterase that catalyzes the hydrolysis of cocaine and heroin. J. Biol. Chem., 272: 14769-14775 (1997).
12. Potter, P. M., Wolverton, J. S., Morton, C. L., Wierdl, M. and Danks, M. K.: Cellular localization domains of a rabbit and a human carboxylesterase: influence on irinotecan (CPT-11) metabolism by the rabbit enzyme. Cancer Res., 58: 3627-3632 (1998).
13. Tabata, T., Katoh, M., Tokudome, S., Nakajima, M. and Yokoi, T.: Identification of the cytosolic carboxylesterase catalyzing the 5$-deoxy-5-fluorocytidine formation from capecitabine in human liver. Drug Metab. Dispos., 32: 1103-1110 (2004).
14. Takai, S., Matsuda, A., Usami, Y., Adachi, T., Sugiyama, T., Katagiri, Y., Tatematsu, M. and Hirano, K.: Hydrolytic profile for ester-or amide-linkage by carboxylesterases pI 5.3 and pI 4.5 from human liver. Biol. Pharm. Bull., 20: 869-873 (1997).
15. Sun, Z., Murry, D. J., Sanghani, S. P., Davis, W. I., Kedishvili, N. Y., Zou, Q., Hurley, T. D. and Bosron, W. F.: Methylphenidate is stereoselectively hydrolyzed by human carboxylesterase CES1A1. J. Pharmacol. Exp. Ther., 310: 469-476 (2004).
16. Shi, D., Yang, J., Yang, D., LeCluyse, E. L., Black, C., You, L., Akhlaghi, F. and Yan, B.: Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by anitplatelet agent clopidogrel. J. Pharmacol. Exp. Ther., 319: 1477-1484 (2006).
17. Tang, M., Mukundan, M., Yang, J., Charpentier, N., LeCluyse, E. L., Black, C., Yang, D., Shi, D. and Yan, B.: Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol. J. Pharmacol. Exp. Ther., 319: 1467-1476 (2006).
18. Tabata, T., Katoh, M., Tokudome, S., Hosokawa, M., Chiba, K., Nakajima, M. and Yokoi, T.: Bioactivation of capecitabine in human liver: Involvement of the cytosolic enzyme on 5$-deoxy-5-fluorocytidine formation. Drug Metab. Dispos., 32: 762-767 (2004).
19. Sato, Y., Miyashita, A., Iwatsubo, T. and Usui, T.: Conclusive identification of the oxybutinin-hydrolyzing enzyme in human liver. Drug Metab. Dispos., 40: 902-906 (2012).
20. Humerickhouse, R., Lohrbach, L., Li, L., Borson, W. F. and Dolan, M. E.: Characterization of irinotecan hydrolysis by human liver carboxyelsterase isoforms hCE-1 and hCE-2. Cancer Res., 60: 1189-1192 (2000).
21. Williams, E. T., Jones, K. O., Ponsler, G. D., Lowery, S. M., Perkins, E. J., Wrighton, S. A., Ruterbories, K. J., Kazui, M. and Farid, N. A.: The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2. Drug Metab. Dispos., 36: 1227-1232 (2008).
22. Zhu, H. J., Patrick, K. S., Yuan, H. J., Wang, J. S., Donovan, J. L., DeVane, C. L., Malcolm, R., Johnson, J. A., Youngblood, G. L., Sweet, D. H., Langaee, T. Y. and Markowitz, J. S.: Two CES1 gene mutations lead to dysfunctional carboxylesterase1 activity in man: clinical significance and molecular basis. Am. J. Hum. Genet., 82: 1241-1248 (2008).
23. Zhu, H. J., Appel, D. I., Johnson, J. A., Chavin, K. D. and Markowitz, J. S.: Role of carboxylesterase 1 and impact of natural genetic variants on the hydrolysis of trandolapril. Biochem. Pharmacol., 77: 1266-1272 (2009).
24. Kubo, T., Kim, S.-R., Sai, K., Saito, Y., Nakajima, T., Matsumoto, K., Saito, H., Shirao, K., Yamamoto, N., Minami, H., Ohtsu, A., Yoshida, T., Saijo, N., Ohno, Y., Ozawa, S. and Sawada, J.-I.: Functional characterization of three naturally occurring single nucleotide polymorphisms in the CES2 gene encoding carboxylesterase 2 (HCE-2). Drug Metab. Dispos., 33: 1482-1487 (2005).
25. Fukami, T., Takahashi, S., Nakagawa, N., Maruichi, T., Nakajima, M. and Yokoi, T.: In vitro evaluation of inhibitory effects of antidiabetic and antihyperlipidemic drugs on human carboxylesterase activities. Drug Metab. Dispos., 38: 2173-2178 (2010).
26. Ovnic, M., Swank, R. T., Fletcher, C., Zhen, L., Novak, E. K., Baumann, H., Heintz, N. and Ganschow, R. E.: Characterization and functional expression of a cDNA enzoding egasyn (esterase-22): the endoplasmic reticulum-targeting protein of β-glucuronidase. Genomics, 11: 956-967 (1991).
27. Li, B., Sediacek, M., Manoharan, I., Boopathy, R., Duysen, E. G., Masson, P. and Lockridge, O.: Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. Biochem. Pharmacol., 70: 1673-1684 (2005).
28. Morton, C. L., Iacono, L., Hyatt, J. L., Taylor, K. R., Cheshire, P. J., Houghton, P. J., Danks, M. K., Stewart, C. F. and Potter, P. M.: Activation and antitumor activity of CPT-11 in plasma esterase-deficient mice. Cancer Chemother. Pharmacol., 56: 629-636 (2005).
29. Luan, L., Sugiyama, T., Takai, S., Usami, Y., Adachi, T., Katagiri, Y. and Hirano, K.: Purification and characterization of pranlukast hydrolase from rat liver microsomes: the hydrolase is identical to carboxylesterase pI 6.2. Biol. Pharm. Bull., 20: 71-75 (1997).
30. Frick, C., Atanasov, A. G., Arnold, P., Ozols, J. and Odermatt, A.: Appropriate function of 11β-hydroxysteroid dehydrogenase type 1 in the endoplasmic reticulum lumen is dependent on its Nterminal region sharing similar topological determinants with 50-kDa esterase. J. Biol. Chem., 279: 31131-31138 (2004).
31. Probst, M. R., Jenö, P. and Meyer, U. A.: Purification and characterization of a human liver arylacetamide deacetylase. Biochem. Biophys. Res. Commun., 177: 453-459 (1991).
32. Probst, M. R., Beer, M., Beer, D., Jeno, P., Meyer, U. A. and Gasser, R.: Human liver arylacetamide deacetylase. Molecular cloning of a novel esterase involved in the metabolic activation of arylacetamide carcinogens with high sequence similarity to hormone-sensitive lipase. J. Biol. Chem., 269: 21650-21656 (1994).
33. Tiwari, R., Koffel, R. and Schneiter, R.: An acetylation/ deacetylation cycle controls the export of sterols and steroid from S. cerevisiae. EMBO J., 26: 5109-5119 (2007).
34. Thole, Z., Manso, G., Salgueiro, E., Revuelta, P. and Hidalgo, A.: Hepatotoxicity induced by antiandrogens: a review of the literature. Urol. Int., 73: 289-295 (2004).
35. Fau, D., Eugene, D., Berson, A., Letteron, P., Fromenty, B., Fisch, C. and Pessayre, D.: Toxicity of the antiandrogen flutamide in isolated rat hepatocytes. J. Pharmacol. Exp. Ther., 269: 954-962 (1994).
36. Katchen, B. and Buxbaum, S.: Disposition of a new, nonsteroid, antiandrogen, α, α, α-trifluoro-2-methyl-4$-nitro-m-propionotoluidine (Flutamide), in men following a single oral 200 mg dose. J. Clin. Endocrinol. Metab., 41: 373-379 (1975).
37. Schulz, M., Scmoldt, A., Donn, F. and Becker, H.: The pharmacokinetics of flutamide and its metabolites after a single oral dose and during chronic treatment. Eur. J. Clin. Pharmacol., 34: 633-636 (1988).
38. Kobayashi, Y., Fukami, T., Shimizu, M., Nakajima, M. and Yokoi, T.: Contributions of arylacetamide deacetylase and carboxylesterase 2 to flutamide hydrolysis in human liver. Drug Metab. Dispos., 40: 1080-1084 (2012).
39. Uetrecht, J.: N-oxydation of drugs associated with idiosyncratic drug reactions. Drug Metab. Rev., 34: 651-665 (2002).
40. Aizawa, Y., Ikemoto, I., Kishimoto, K., Wada, T., Yamazaki, H., Ohishi, Y., Kiyota, H., Furuta, N., Sunuki, H. and Ueda, M.: Flutamide-induced heoatic dysfunction in relation to steady-state plasma concentrations of flutamide and its metabolites. Mol. Cell. Biochem., 252: 149-156 (2003).
41. Matsuzaki, Y., Nagai, D., Ichimura, E., Goda, R., Tomura, A., Doi, M. and Nishikawa, K.: Metabolism and hepatic toxicity of flutamide in cytochrome P450 1A2 knockout SV129 mice. J. Gastroenterol., 41: 231-239 (2006).
42. Ohbuchi, M., Miyata, M., Nagai, D., Shimada, M., Yoshinari, K. and Yamazoe, Y.: Role of enzymatic N-hydroxylation and reduction in flutamide metabolite-induced liver toxicity. Drug Metab. Dispos., 37: 97-105 (2009).
43. Sicardi, S. M., Martiarena, J. L. and Iglesias, M. T.: Mutagenic and analgesic activities of aniline derivatives. J. Pharm. Sci., 80: 761-764 (1991).
44. Gago-Dominguez, M., Yuan, J. M., Castelao, J. E., Ross, R. K. and Yu, M. C.: Regular use of analgesics is a risk factor for renal cell carcinoma. Br. J. Cancer, 81: 542-548 (1999).
45. Vaught, J. B., McGarney, P. B., Lee, M. S., Garner, C. D., Wang, C. Y., Linsmainer-Bednar, E. M. and King, C. M.: Activation of N-hydroxyphenacetin to mutagenic and nucleic acidbinding metabolites by acyltransfer, deacylation, and sulfate conjugation. Cancer Res., 41: 3424-3429 (1981).
46. Wirth, P. J., Alewood, P., Calder, I. and Thorgeirsson, S. S.: Mutagenecity of N-hydroxy-2-acetylaminofluorene and N-hydroxy-phenacetin and their respective deacetylated metabolites in nitroreductase deficient Salmonella TA98FR and TA100FR. Carcinogenesis, 3: 167-170 (1982).
47. Jensen, C. B. and Jollow, D. J.: The role of N-hydroxyphenetidine in phenacetin-induced hemolytic anemia. Toxicol. Appl. Pharmacol., 111: 1-12 (1991).
48. Kobayashi, Y., Fukami, T., Higuchi, R., Nakajima, M. and Yokoi, T.: Metabolic activation by human arylacetamide deacetylase, CYP2E1, and CYP1A2 causes phenacetin-induced methemoglobinemia. Biochem. Pharmacol., in press.
49. Yew, W. W. and Leung, C. C.: Antituberculosis drugs and hepatotoxicity. Respirology, 11: 699-707 (2006).
50. Shimizu, M., Fukami, T., Kobayashi, Y., Takamiya, M., Aoki, Y., Nakajima, M. and Yokoi, T.: A novel polymorphic allele of human arylacetamide deacetylase leads to diminished enzyme activity. Drug Metab. Dispos., 40: 1183-1190 (2012).
51. Kobayashi, Y., Fukami, T., Nakajima, A., Watanabe, A., Nakajima, M. and Yokoi, T.: Species differences in tissue distribution and enzyme activities of arylacetamide deacetylase in human, rat, and mouse. Drug Metab. Dispos., 40: 671-679 (2012).
52. Tenconi, L. T. and Beretta, E.: Urinary and biliary metabolites of rifampicin in different animal species. In: The Problems of Species Differences and Statistics in Toxicology, Proc. Europ. Soc. For study of drug Toxicity, Vol. II; Excerpta Med. Int. Congr. Ser. No. 198, Excerpta Medica, Amsterdam, pp. 80-85 (1970).
53. Chan, K.: A simultaneous determination of rifampin and 25-deacetylrifampicin in cerebrospinal fluid and plasma of rabbit by liquid chromatography. Zhongguo. Yao. Li. Xue. Bao., 8: 555-559 (1987).
54. Binda, G., Domenichini, E., Gottardi, A., Orlandi, B., Ortelli, E., Pacini, B. and Fowst, G.: Rifampicin, a general review. Arzneimittelforschung, 21: 1907-1977 (1971).
55. Gnatt, A., Ginzberg, D., Lieman-Hurwitz, J., Zamir, R., Zakut, H. and Soreq, H.: Human acetylcholinesterase and butyrylcholinesterase are encoded by two distinct genes. Cell. Mol. Neurobiol., 11: 91-104 (1991).
56. Karpel, R., Ben Aziz-Aloya, R., Sternfeld, M., Ehrlich, G., Ginzberg, D., Tarroni, P., Clementi, F., Zakut, H. and Soreq, H.: Expression of three alternative acetylcholinesterase messenger RNAs in human tumor cell lines of different tissue origins. Exp. Cell Res., 210: 268-277 (1994).
57. Chatonnet, A. and Lockridge, O.: Comparison of butyrylcholinesterase and acetylcholinesterase. Biochem. J., 260: 625-634 (1989).
58. Takeda, M., Tanaka, T. and Okochi, M.: New drugs for Alzheimerös disease in Japan. Psychiatry Clin. Neurosci., 65: 399-404 (2011).
59. Jbilo, O., Bartels, C. F., Chatonnet, A., Toutant, J. P. and Lockridge, O.: Tissue distribution of human acetylcholinesterase and butyrylcholinesterase messenger RNA. Toxicon, 32: 1445-1457 (1994).
60. Lockridge, O., Bartels, C. F., Vaughan, T. A., Wong, C. K., Norton, S. E. and Johnson, L. L.: Complete amino acid sequence of human serum cholinesterase. J. Biol. Chem., 262: 549-557 (1987).
61. Pérez Guillermo, F., Martinez Pretel, C. M., Tarín Royo, F., Peña Macias, M. J., Alvarez Ossorio, J. A. and Vidal, C. J.: Prolonged suxamethonium-induced neuromuscular blockade asso-ciated with organophosphate poisoning. Br. J. Anaesth., 61: 233-236 (1988).
62. Østergaard, D., Jensen, F. S., Jensen, E., Skovgaard, L. T. and Viby-Mogensen, J.: Mivacurium-induced neuromuscular blockade in patients with atypical plasma cholinesterase. Acta Anaesthesiol. Scand., 37: 314-318 (1993).
63. Vaisi-Raygani, A., Rahimi, Z., Kharazi, H., Tavilani, H., Aminiani, M., Kiani, A., Vaisi-Raygani, A. and Pourmotabbed, T.: Determination of butyrylcholinesterase (BChE) phenotypes to predict the risk of prolonged apnea in persons receiving succinylcholine in the healthy population of western Iran. Clin. Biochem., 40: 629-633 (2007).
64. Stewart, D. J., Inaba, T., Lucassen, M. and Kalow, W.: Cocaine metabolism: Cocaine and norcocaine hydrolysis by liver and serum esterases. Clin. Pharmacol. Ther., 25: 464-468 (1979).
65. Morton, C. L., Wadkins, M., Danks, M. K. and Potter, P. M.: The anticancer prodrug CPT-11 is a potent inhibitor of acetylcholinesterase but is rapidly catalyzed to SN-38 by butyrylcholinesterase. Cancer Res., 59: 1458-1463 (1999).
66. Kuo, C. L. and La Du, B. N.: Calcium binding by human and rabbit serum paraoxonases. Structural stability and enzymatic activity. Drug Metab. Dispos., 26: 653-660 (1998).
67. Primo-Parmo, S. L., Sorenson, R. C., Teiber, J. and La Du, B. N.: The human serum paraoxonase/arylesterase gene (PON1) is one member of a multiple family. Genomics, 33: 498-507 (1996).
68. Draganov, D. I. and La Du, B. N.: Pharmacogenetics of paraoxonases: a brief review. Naunyn Schmiedebergs Arch. Pharmacol., 369: 78-88 (2004).
69. Ng, C. J., Wadleigh, D. J., Gangopadhyay, A., Hama, S., Grijalva, V. R., Navab, M., Fogelman, A. M. and Reddy, S. T.: Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J. Biol. Chem., 276: 44444-44449 (2001).
70. Gonzalvo, M. C., Gil, F., Hernandez, A. F., Rodrigo, L., Villanueva, E. and Pla, A.: Human liver paraoxonase (PON1): subcellular distribution and characterization. J. Biochem. Mol. Toxicol., 12: 61-69 (1998).
71. Gaidukov, L. and Tawfik, D. S.: High affinity, stability, and lactonase activity of serum paraoxonase PON1 anchored on HDL with ApoA-I. Biochemistry, 44: 11843-11854 (2005).
72. Aldridge, W. N.: Serum esterase I. Two types of esterase (A and B) hydrolyzing p-nitrophenyl acetate, propionate and butyrate and a method for their determination. Biochem. J., 53: 110-117 (1953).
73. Davies, H. G., Richter, R. J., Keifer, M., Broomfield, C. A., Sowalla, J. and Furlong, C. E.: The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat. Genet., 14: 334-336 (1996).
74. Tougou, K., Nakamura, A., Watanabe, S., Okuyama, Y. and Morino, A.: Paraoxonase has a major role in the hydrolysis of prulifloxacin (NM441), a prodrug of a new antifloxacin agent. Drug Metab. Dispos., 26: 355-359 (1998).
75. Hioki, T., Fukami, T., Nakajima, M. and Yokoi, T.: Human paraoxonase 1 is the enzyme responsible for pilocarpine hydrolysis. Drug Metab. Dispos., 39: 1345-1352 (2011).
76. Ishizuka, T., Fujimori, I., Nishida, A., Sakurai, H., Yoshigae, Y., Nakahara, K., Kurihara, A., Ikeda, T. and Izumi, T.: Paraoxonase 1 as a major bioactivating hydrolase for olmesartan medoxomil in human blood circulation: molecular identification and contribution to plasma metabolism. Drug Metab. Dispos., 40: 374-380 (2012).
77. Billecke, S., Draganov, D., Counsell, R., Stetson, P., Watson, C., Hsu, C. and La Du, B. N.: Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab. Dispos., 28: 1335-1342 (2000).
78. Scacchi, R., Corbo, R. M., Rickards, O. and De Stefano, G. F.: New data on the world distribution of paraoxonase (PON1 Gln 192 G Arg) gene frequencies. Hum. Biol., 75: 365-373 (2003).
79. Ueno, T., Shimazaki, E., Matsumoto, T., Watanabe, H., Tsunemi, A., Takahashi, Y., Mori, M., Hamano, R., Fujioka, T., Soma, M., Matsumoto, K. and Kanmatsuse, K.: Paraoxonase1 polymorphism Leu-Met55 is associated with cerebral infarction in Japanese population. Med. Sci. Monit., 9: CR208-CR212 (2003).
80. Chen, J., Kumar, M., Chan, W., Berkowitz, G. and Wetmur, J. G.: Increased influence of genetic variation on PON1 activity in neonates. Environ. Health Perspect., 111: 1403-1409 (2003).
81. Garin, M. C., James, R. W., Dussoix, P., Blanché, H., Passa, P., Froguel, P. and Ruiz, J.: Paraoxonase polymorphism Met-Leu 54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and icreased risk of cardiovascular disease in diabetes. J. Clin. Invest., 99: 62-66 (1997).
82. Mackness, B., Mackness, M. I., Arrol, T., Turkie, W. and Durrington, P. N.: Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modifications. FEBS Lett., 423: 57-60 (1998).
83. Brophy, V. H., Hastings, M. D., Clendenning, J. B., Richter, R. J., Jarvik, G. P. and Furlong, C. E.: Polymorphisms in the human paraoxonase (PON1) promoter. Pharmacogenetics, 11: 77-84 (2001).
84. Teiber, J. F., Horke, S., Haines, D. C., Chowdhary, P. K., Xiao, J., Kramer, G. L., Haley, R. W. and Draganov, D. I.: Dominant role of paraoxonases in inactivation of the Pseudomonas aeruginosa quorum-sensing signal N-(3-oxododecanoyl)-L-homoserine lactone. Infect. Immun., 76: 2512-2519 (2008).
85. Draganov, D. I., Teiber, J. F., Speelman, A., Osawa, Y., Sunahara, R. and La Du, B. N.: Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J. Lipid Res., 46: 1239-1247 (2005).
86. Campo, S., Sardo, A. M., Campo, G. M., Avenoso, A., Castalbo, M., DöAscola, A., Giunta, E., Calatroni, A. and Saitta, A.: Identification of paraoxonase 3 gene (PON3) missense mutations in a population of southern Italy. Mutat. Res., 546: 75-80 (2004).
87. Sanghera, D. K., Manzi, S., Minster, R. L., Shaw, P., Kao, A., Bontempo, F. and Kamboh, M. I.: Genetic variation in the paraoxonase-3 (PON3) gene is associated with serum PON1 activity. Ann. Hum. Genet., 72: 72-81 (2008).
88. Evans, W. E. and Relling, M. V.: Pharmacogenomics: translating functional genomics into rational therapeutics. Science, 286: 487-491 (1999).
89. Spahn-Langguth, H. and Benet, L. Z.: Acyl glucuronides revisited: is the glucuronidation process a toxification as well as a detoxification mechanism? Drug Metab. Rev., 24: 5-47 (1992).
90. Bullingham, R. E., Nicholls, A. J. and Kamm, B. R.: Clinical pharmacokinetics of mycophenolate mofetil. Clin. Pharmacokinet., 34: 429-455 (1998).
91. Shipkova, M., Armstrong, V. W., Wieland, E., Niedmann, P. D., Schütz, E., Brennerr-Weiss, G., Voihsel, M., Braun, F. and Oellerich, M.: Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Br. J. Pharmacol., 126: 1075-1082 (1999).
92. Wieland, E., Shipkova, M., Schellhaas, U., Schütz, E., Niedmann, P. D., Armstrong, V. W. and Oellerich, M.: Induction of cytokine release by the acyl glucuronide of mycophenolic acid: a link to side effects? Clin. Biochem., 33: 107-113 (2000).
93. Shipkova, M., Beck, H., Voland, A., Armstrong, V. W., Gröne, H. J., Oellerich, M. and Wieland, E.: Identification of protein targets for mycophenolic acid acyl glucuronide in rat liver and colon tissue. Proteomics, 4: 2728-2738 (2004).
94. Suzuki, E., Yamamura, N., Ogura, Y., Nakai, D., Kubota, K., Kobayashi, N., Miura, S. and Okazaki, O.: Identification of valproic acid glucuronide hydrolase as a key enzyme for the interaction of valproic acid with carbapenem antibiotics. Drug Metab. Dispos., 38: 1538-1544 (2010).
95. Perrier, J., Durand, A., Giardina, T. and Puigserver, A.: Catabolism of intracellular N-terminal acetylated proteins: involvement of acylpeptide hydrolase and acylase. Biochimie, 87: 673-685 (2005).
96. Nagai, K., Shimizu, T., Toga, A., Takeya, M., Yokomizo, Y., Sakata, Y., Matsuishi, T. and Kato, H.: Decrease in serum levels of valproic acid during treatment with a new carbapenem, panipenem/betamipron. J. Antimicrob. Chemother., 39: 295-296 (1997).
97. Volland, C., Sun, H., Dammeyer, J. and Benet, L. Z.: Stereoselective degradation of the fenoprofen acyl glucuronide enatiomers and irreversible binding to plasma protein. Drug Metab. Dispos., 19: 1080-1086 (1991).
98. Smith, P. C., Song, W. Q. and Rodriguez, R. J.: Covalent binding of etodolac acyl glucuronide to albumin in vitro. Drug Metab. Dispos., 20: 962-965 (1992).
99. Dubois-Presle, N., Lapicque, F., Maurice, M., Fournel-Gigleux, S., Magdalou, J., Abiteboul, M., Siest, G. and Netter, P.: Stereoselective esterase activity of human serum albumin toward ketoprofen glucuronide. Mol. Pharmacol., 47: 647-653 (1995).
100. Sallustio, B. C., Fairchild, B. A. and Pannall, P. R.: Interaction of human serum albumin with the electrophilic metabolite 1-Ogemfibrozil-β-D-glucuronide. Drug Metab. Dispos., 25: 55-60 (1997).
101. Hervé, F., Urien, S., Albengres, S., Duche, J. C. and Tillement, J. P.: Drug binding in plasma. A summary of recent trends in the study of drug and hormone binding. Clin. Pharmacokinet., 26: 44-58 (1994).
102. Qiu, Y., Burlingame, A. L. and Benet, L. Z.: Mechanisms for covalent binding of benoxaprofen glucuronide to human serum albumin. Studies by tandem mass spectrometry. Drug Metab. Dispos., 26: 246-256 (1998).
103. Rowe, B. J. and Meffin, P. J.: Diisopropylfluorophosphate increases clofibric acid clearance: supporting evidence for a futile cycle. J. Pharmacol. Exp. Ther., 230: 237-241 (1984).
104. Smith, P. C., McDonagh, A. F. and Benet, L. Z.: Effect of esterase inhibition on the disposition of zomepirac glucuronide and its covalent binding to plasma proteins in the guinea pig. J. Pharmacol. Exp. Ther., 252: 218-224 (1990).
105. Whiting, J. F., Narciso, J. P., Chapman, V., Ransil, B. J., Swank, R. T. and Gollan, J. L.: Deconjugation of bilirubin-IXα glucuronides: a physiolosic role of hepatic microsomal βglucuronidase. J. Biol. Chem., 268: 23197-23201 (1993).
106. Takematsu, H., Diaz, S., Stoddart, A., Zhang, Y. and Varki, A.: Lysosomal and cytosolic sialic acid 9-O-acetylesterase activities can be encoded by one gene via differential usage of a single peptideencoding exon at the N terminus. J. Biol. Chem., 274: 25623-25631 (1999).
107. Usui, S., Kubota, M., Iguchi, K., Kiho, T., Sugiyama, T., Katagiri, Y. and Hirano, K.: Sialic acid 9-O-acetylesterase catalyzes the hydrolyzing reaction from alacepril to deacetylalacepril. Pharm. Res., 20: 1309-1316 (2003).
108. Ishizuka, T., Fujimori, I., Kato, M., Noji-Sakikawa, C., Saito, M., Yoshigae, Y., Kubota, K., Kurihara, A., Izumi, T., Ikeda, T. and Okazaki, O.: Human carboxymethylenebutenolidase as a bioactivation hydrolase of olmesartan medoxomil in liver and intestine. J. Biol. Chem., 285: 11892-11902 (2010).
109. Laeis, P., Püchler, K. and Kirch, W.: The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. J. Hypertens. Suppl., 19: S21-S32 (2001).
110. Weller, S., Blum, M. R., Doucette, M., Burnette, T., Cederberg, D. M., de Miranda, P. and Smiley, M. L.: Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single-and multiple-dose administration to normal volunteers. Clin. Pharmacol. Ther., 54: 595-605 (1993).
111. Kim, I., Chu, X. Y., Kim, S., Provoda, C. J., Lee, K. D. and Amidon, G. L.: Identification of a human valacyclovirase: biphenyl hydrolase-like protein as valacyclovir hydrolase. J. Biol. Chem., 278: 25348-25356 (2003).
112. Puente, X. S. and López-Otín, C.: Cloning and expression analysis of a novel human serine hydrolase with sequence similarity to prokaryotic enzymes involved in the degradation of aromatic compounds. J. Biol. Chem., 270: 12926-12932 (1995).
113. Lai, L., Xu, Z., Zhou, J., Lee, K. D. and Amidon, G. L.: Molecular basis of prodrug activation by human valacyclovirase, an α-amino acid ester hydrolase. J. Biol. Chem., 283: 9318-9327 (2008).
114. Kim, I., Song, X., Vig, B. S., Mittal, S., Shin, H. C., Lorenzi, P. J. and Amidon, G. L.: A novel nucleoside prodrug-activating enzyme: substrate specificity of biphenyl hydrolase-like protein. Mol. Pharm., 1: 117-127 (2004).
115. Zhou, G., Marathe, G. K., Willard, B. and McIntyre, T. M.: Intracellular erythrocyte platelet-activating factor acetylhydrolase I inactivates aspirin in blood. J. Biol. Chem., 286: 34820-34829 (2011).
116. Sidhu, R. S. and Blair, A. H.: Human liver aldehyde dehydrogenase. Esterase activity. J. Biol. Chem., 250: 7894-7898 (1975).
117. Wei, B., Ni, L., Hurley, T. D. and Weiner, H.: Cooperativity in nicotinamide adenine dinucleotide binding induced by mutations of arginine 475 located at the subunit interface in the human liver mitochondrial class 2 aldehyde dehydrogenase. Biochemistry, 39: 5295-5302 (2000).
118. Parajuli, B., Kimble-Hill, A. C., Khanna, M., Ivanova, Y., Meroueh, S. and Hurley, T. D.: Discovery of novel regulators of aldehyde dehydrogenase isoenzymes. Chem. Biol. Interact., 191: 153-158 (2011).
119. Mackenzie, I. S., Maki-Petaja, K. M., McEniery, C. M., Bao, Y. P., Wallace, S. M., Cheriyan, J., Monteith, S., Brown, M. J. and Wilkinson, I. B.: Aldehyde dehydrogenase 2 plays a role in the bioactivation of nitroglycerin in humans. Arterioscler. Thromb. Vasc. Biol., 25: 1891-1895 (2005).
120. Li, Y., Zhang, D., Jin, W., Shao, C., Yan, P., Xu, C., Sheng, H., Liu, Y., Yu, J., Xie, Y., Zhao, Y., Lu, D., Nebert, D. W., Harrison, D. C., Huang, W. and Jin, L.: Mitochondrial aldehyde dehydrogenase-2 (ALDH2) Glu504Lys polymorphism contributes to the variation in efficacy of sublingual nitroglycerin. J. Clin. Invest., 116: 506-511 (2006).